Table 2.
Peripheral T-cell lymphoma biomarkers*
| Recommendations | Standard of care | Integral | Integrated | Exploratory | Validated | Identifies high-/low-risk groups | Identifies therapeutic target | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Histopathology | ||||||||||
| Complete immunophenotypic panel by flow cytometry and/or immunohistochemistry for CD3, CD4, CD8, CD30, etc. | Yes | Yes | Yes | No | Yes | Yes | No | |||
| Disease-specific phenotype: ALK, CD2, CD5, CD7, CD56, EBV (EBER ISH), PD1, granzyme, perforin, TIA1, BetaF1, TCR-GM1 | Yes | Yes | Yes | No | Yes | Yes | No | |||
| Molecular/genetic | ||||||||||
| Targeted mutational panel for known PTCL mutations (eg, TET2, IDH2, DNMT3A, FYN, RHOA, CD28, Stat5b in gamma-delta subtype) | No | No | Yes | Yes | No | Yes | Yes | |||
| GEP for diagnostic signatures (GATA3, TBX1, gamma-delta) | No | No | No | Yes | No | Yes | Maybe | |||
ALK = anaplastic lymphoma kinase; Beta F1 = T-cell beta chain antigen receptor; CD = complement of differentiation; DNMT3A = DNA (cytosine-5-)-methyltransferase 3 alpha; EBER ISH = Epstein Barr virus in situ hybridization; EBV = Epstein Barr virus; FYN = tyrosine kinase Fyn; GATA3 = T-cell-specific transcription factor binds to the sequence G-A-T-A; GEP = gene expression profiling; IDH2 = isocitrate dehydrogenase gene; PD1 = programmed death 1; RHOA = Ras homolog gene family, member A, a GTPase protein of the Rho family; Stat5b = signal transducer and activator of transcription 5B; TBX1 = T box 1 gene; TCR-GM1 = T-cell receptor glycosphingolipid; TET2 = Tet methylcytosine dioxygenase 2 gene; TIA1 = T-cell intracytoplasmic antigen.